LYRA Lyra Therapeutics Inc. Total Asset Value of Company

LYRA (Lyra Therapeutics, Inc) - company brandmark

The historical price action for the total assets of Lyra Therapeutics, Inc. (LYRA), recorded at 0.00, complements the profile of a brand renowned for high-quality ENT therapy methods. The company is currently revising its development portfolio following failed trials, focusing on securing licensees and independent survival. The company's US capabilities are based on innovative targeted drug delivery systems that eliminate the need for surgical intervention.

LYRA (Lyra Therapeutics, Inc.) Company Total Assets history from 07/04/2022 to 03/28/2026

Analytical breakdowns and data insights for company Lyra Therapeutics, Inc (LYRA)

- market value and analyst target forecast:
Stock Price lyratherapeutics.com|LYRA - Price Target Chart
- market capitalization data:
Market Valuation Lyra Therapeutics Inc|LYRA - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Lyra Therapeutics|LYRA - Book Capitalization|Market Capitalization to Book Value Ratio lyratherapeutics.com|LYRA - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Lyra Therapeutics, Inc.|LYRA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Lyra Therapeutics Inc|LYRA - Company Aggregate Debts|Debts to Book Capitalization Lyra Therapeutics Inc|LYRA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Lyra Therapeutics|Immediate Liquidity lyratherapeutics.com
- net income and valuation multiples indicators:
LYRA - Net Income
Fundamental valuation:Lyra Therapeutics, Inc.
Manufactured products of Lyra Therapeutics, Inc.

For Lyra Therapeutics, Inc. (LYRA), the total value of resources is critically dependent on the success of its drug delivery platform and the outcome of Phase 3 clinical trials. This metric, calculated inversely via ROA, measures the total value of assets and liabilities, while the company's assets by ROA allow for the tracking of capital volatility between reports, signaling drawdown risks in the event of declining business margins.

Key competitors

haleon.com (HLN) - Company Total Assets|Aggregate Company Assets Kenvue|Verona Pharma PLC - Total Asset Value of Company|Company Total Assets MENS|LGND (Ligand Corp) - Aggregate Asset Value|Company Total Assets AMRX (Amneal Pharmaceuticals)|Company Total Assets perrigo.com PRGO|ALVO - Aggregate Company Assets|Aggregate Asset Value LQDA (Liquidia Corp)|Galapagos Genomics (GLPG) - Aggregate Company Assets|Cumulative Company Assets ANI Pharmaceuticals Corp|MNKD (MannKind Corporation) - Company Total Assets|Company Total Assets amphastar.com|Cumulative Company Assets PCRX (Pacira BioSciences, Inc.)|SPRY (ARS Pharmaceuticals Inc) - Aggregate Asset Value|Aggregate Company Assets Theravance TBPH|Aquestive Corp (AQST) - Company Assets|SCPH: Cumulative Company Assets|Tectonic Therapeutic, Inc. - Aggregate Business Assets|TNXP: Company Total Assets|China SXT Pharmaceuticals, Inc. - Aggregate Asset Value|EPRX (Eupraxia Pharmaceuticals, Inc.) - Company Total Assets|Company Assets BioHarvest Sciences Inc BHST|Aggregate Company Assets eXoZymes Inc (EXOZ)|ORMP (oramed.com) - Aggregate Asset Value|Aggregate Company Assets Entera Bio ENTX|MindWalk Holdings, Inc. - Aggregate Company Assets|ABVC: Cumulative Company Assets|Company Assets Cumberland Corp|Quantum BioPharma Ltd (QNTM) - Aggregate Company Assets|fibrogen.com - Aggregate Asset Value|TELO (Telomir Pharmaceuticals, Inc.) - Company Total Assets|Company Total Assets Rani Therapeutics Inc|Cumulative Company Assets SNYR (Synergy CHC Corp)|RLYB (rallybio.com) - Aggregate Asset Value|Lexaria Bioscience Corp. - Cumulative Company Assets|Aggregate Business Assets PULM (pulmatrix.com)|Pheton - Company Total Assets|Aggregate Asset Value APM (Aptorum Group Limited)|IBO: Company Total Assets|Company Assets TNF Pharmaceuticals, Inc. (TNFA)|Aggregate Company Assets cbdMD Inc.|PRFX: Aggregate Asset Value|Company Total Assets CYTO|Company Total Assets Lipella Pharmaceuticals Inc (LIPO)|Aggregate Company Assets Optinose OPTN|PIRS (Pieris Pharma) - Total Asset Value of Company|Procaps Group S.A. - Company Total Assets|Company Assets petrospharma.com|QLI (Qilian International Holding) - Cumulative Company Assets|Acelyrin Inc. (SLRN) - Company Total Assets|Cumulative Company Assets TFFP